The initial target markets are for Research & Development (R&D) NIR-II surgical workstation product sales (1H2018 sales) and clinical NIR-II surgical workstation product sales (human med, 2019-2020 and veterinary med, 2019 approvals anticipated) with a focus on cancer surgery.

Eagle Eye will initially enter this market via major medical device distributor(s) in the USA, PRC, and EU.

Academic R&D institutions have immediate unmet needs for NIR-II surgical workstation and imaging devices, reagent kits, and Rx/Dx products for R&D purposes.

  • The global life science reagents market for 2019 is estimated at US$26B
  • By end user, the research and academics segment will continue to remain the dominant segment, accounting for 37% of the market by 2019
  • The North America life science reagents market will be $10.3B by 2019
  • Asia Pacific is expected to expand at a high CAGR from 2013 to 2019

The key characteristics that make them have this need are the need for better outcomes in their R&D research. Primary clinical institutions customers include:

  • Hospitals
  • Surgery Centers
  • Clinics
  • Offices 
  • Mobile Medical Stations
  • Other

There are approximately 81,315 hospitals, worldwide. It is estimated that only 30% of these hospitals are equipped to provide NIR-II Surgical Workstations to their respective patient populations.

The NIR-II Surgical Imaging Workstations combined with our proprietary NIR-II dye reagent kits has the potential to increase the expansion and adoption of MIS Imaging to an additional 50% of these hospitals by 2020. Nonetheless, the total Global Hospital market potential for Surgical Workstation exceeds $14 Billion annually.